Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONVERGE: JNJ-90301900 plus chemoradiotherapy followed by durvalumab in unresectable stage III NSCLC
CTR20260160Phase 2Active
- Sponsor
- Johnson & Johnson
- Start
- Apr 2026
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of NBTXR3 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Objective response rate by ICR. Started Apr 2026; status: active.
02
Drugs
NBTXR3
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20260160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260160.